Biopharmaceutical venture capital is spurring innovation and economic growth
By Tim McClung | February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...
Read More
In survey, PhRMA member companies highlight impact of IPI on R&D
By Katie Verb | February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....
Read More
Putting 2018 medicine approvals in context
By Andrew Powaleny | January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
